Guide

BPC-157 vs TB-500: Which Repair Peptide Should You Choose?

Last updated: April 14, 2026 · 14 min read · Reviewed by Grey Peptides Editorial Board

TL;DR

BPC-157 and TB-500 are the two most widely used tissue repair peptides, but they work through fundamentally different mechanisms. BPC-157 promotes healing primarily through angiogenesis (new blood vessel formation) and is best used locally near an injury. TB-500 works systemically through cell migration and anti-inflammatory pathways. They are frequently stacked together for synergistic effects — and for good reason. If you're choosing only one, BPC-157 has more published research and is the better starting point for beginners. If you're dealing with systemic inflammation or widespread tissue damage, TB-500 may be more appropriate. For maximum repair potential, the BPC-157 + TB-500 stack is the most commonly used combination in the peptide space.

→ Compare them side-by-side with real-time data in our Comparison Tool.

The 60-Second Overview
Head-to-Head Comparison Table
BPC-157: How It Works
TB-500: How It Works
Key Differences That Matter
Which One Should You Choose?
The BPC-157 + TB-500 Stack
Dosing Protocols Compared
Side Effects Compared
Legal Status
Frequently Asked Questions
Sources

The 60-Second Overview

BPC-157 (Body Protection Compound-157) is a 15-amino acid synthetic peptide derived from a protein found in human gastric juice. It was first characterized in the early 1990s and has since accumulated over 120 published studies investigating its effects on tendons, ligaments, muscles, the GI tract, and neurological tissue. Its primary mechanism involves upregulating VEGF (vascular endothelial growth factor) to promote angiogenesis — the formation of new blood vessels that supply healing tissue with nutrients and oxygen.

TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring 43-amino acid peptide that plays a critical role in tissue repair throughout the body. TB-500 works primarily through actin regulation — it binds to G-actin (a structural protein in cells) to promote cell migration, which is how your body moves repair cells to damaged areas. It also has significant anti-inflammatory properties and promotes blood cell formation.

Both peptides promote tissue repair. But they do it through entirely different biological pathways, which is why they're so often used together.

Head-to-Head Comparison Table

Attribute	BPC-157	TB-500
Full Name	Body Protection Compound-157	Thymosin Beta-4 (synthetic)
Amino Acids	15 (pentadecapeptide)	43
Molecular Weight	1,419 Da	4,963 Da
Origin	Human gastric juice	Thymus gland
Primary Mechanism	Angiogenesis (VEGF), NO system	Actin regulation, cell migration
Half-Life	~4 hours	~24 hours
Typical Dose	250–500 mcg/day	2–5 mg, 2x/week
Administration	SubQ (local or systemic)	SubQ (systemic)
Injection Location	Near injury site (preferred)	Any SubQ site (systemic)
Loading Phase	Not typically required	Yes — 4 weeks loading
Cycle Length	4–6 weeks	8–12 weeks
PubMed Studies	120+	75+
Human Clinical Trials	1 (2025 pilot)	0
Monthly Searches (US)	165,000	74,000
YoY Growth	+34%	+28%
US Legal Status	Restricted (reopening)	Restricted (reopening)
Cost (typical vial)	$30–45 (5 mg)	$35–50 (5 mg)

→ See the full interactive comparison with radar chart in our Comparison Tool.

BPC-157: How It Works

BPC-157's tissue repair properties stem from multiple interconnected mechanisms, with angiogenesis at the center.

VEGF Upregulation & Angiogenesis

BPC-157's most well-documented mechanism is its ability to upregulate vascular endothelial growth factor (VEGF) and its receptor VEGFR2. VEGF is the primary signaling molecule that triggers the growth of new blood vessels from existing vasculature. When tissue is damaged, the local blood supply is often disrupted. By promoting new blood vessel formation, BPC-157 helps restore the nutrient and oxygen delivery that healing tissue requires.

This is why BPC-157 is most effective when injected near the injury site — it promotes angiogenesis locally, creating new blood supply directly where it's needed.

Nitric Oxide System Modulation

BPC-157 interacts with the nitric oxide (NO) system, which regulates vasodilation, inflammation, and tissue repair signaling. Research suggests BPC-157 can modulate both NOS (nitric oxide synthase) expression and NO-mediated pathways, contributing to its anti-inflammatory and healing properties.

Growth Hormone Receptor Expression

A 2018 study published in Molecules demonstrated that BPC-157 enhances growth hormone receptor (GHR) expression in tendon fibroblasts. This means BPC-157 may make tissues more responsive to growth hormone — whether endogenous or from GH secretagogue protocols — potentially amplifying the repair environment beyond its own direct effects.

FAK-Paxillin Signaling

BPC-157 activates the focal adhesion kinase (FAK)-paxillin pathway, which is essential for cell adhesion, migration, and tissue organization during wound healing. This mechanism has been observed across multiple tissue types, contributing to BPC-157's reputation as a versatile repair peptide.

Dopaminergic System

Unique among repair peptides, BPC-157 has demonstrated interaction with the dopaminergic system in both in vitro and in vivo studies. This may underlie some of the mood and motivational benefits that users anecdotally report, and it opens up potential applications in neurological recovery research.

→ Read the complete BPC-157 profile in our Encyclopedia.

TB-500: How It Works

TB-500's mechanisms are fundamentally different from BPC-157's, which is precisely why they complement each other so well.

Actin Regulation & Cell Migration

TB-500's primary mechanism involves binding to G-actin (globular actin), a protein that forms the structural scaffolding of cells. By sequestering G-actin, TB-500 promotes the formation of new actin filaments, which are essential for cell movement. This enhanced cell migration is how the body moves fibroblasts, endothelial cells, and immune cells to injury sites to begin the repair process.

This is a systemic mechanism — unlike BPC-157's local angiogenesis, TB-500's effects on cell migration operate throughout the body regardless of injection site. You do not need to inject TB-500 near the injury; any subcutaneous site will deliver systemic effects.

Anti-Inflammatory Properties

TB-500 has significant anti-inflammatory activity, reducing the production of pro-inflammatory cytokines at injury sites. Chronic inflammation is one of the primary barriers to tissue repair — by dampening excessive inflammatory response, TB-500 creates a more favorable healing environment.

Blood Cell Formation

Research has shown that TB-500 promotes the formation of new blood cells, particularly in the context of injury recovery. This hematopoietic effect supports the overall healing process by improving the body's capacity to deliver oxygen and immune cells to damaged tissue.

Tissue Remodeling

TB-500 plays a role in tissue remodeling — the process by which provisional repair tissue (scar tissue) is reorganized into functional tissue. This is particularly relevant for tendon and ligament injuries, where the quality of the healed tissue (not just the speed of healing) determines long-term functional outcomes.

→ Read the complete TB-500 profile in our Encyclopedia.

Key Differences That Matter

1. Local vs Systemic Action

This is the most practically important difference. BPC-157 works best when injected near the injury because its primary mechanism (angiogenesis) is a localized process. TB-500 works systemically — its cell migration effects operate body-wide regardless of injection site.

What this means for you: If you have a specific, localized injury (torn rotator cuff, Achilles tendon, knee ligament), BPC-157 injected near that site is the targeted approach. If you have widespread inflammation, multiple injury sites, or systemic tissue damage, TB-500's systemic action covers more ground.

2. Half-Life & Dosing Frequency

BPC-157 has a short half-life (~4 hours), requiring daily dosing — typically 1–2 times per day. TB-500 has a much longer half-life (~24 hours), allowing for less frequent dosing at 2–3 times per week during loading and once weekly during maintenance.

What this means for you: TB-500 requires fewer injections per week but higher doses per injection. BPC-157 requires daily dosing but at much smaller volumes.

3. Loading Phase

TB-500 protocols typically include a 4-week loading phase at higher frequency (2x/week at 2–5 mg) before transitioning to a maintenance phase (1x/week at 1–2 mg). BPC-157 does not require a loading phase — dosing is consistent from day one.

4. Research Depth

BPC-157 has more published research (120+ studies) and the advantage of a 2025 human safety pilot study showing no serious adverse events at IV doses up to 20 mg. TB-500 has substantial preclinical research (75+ studies) but no published human clinical trials as of 2026.

5. Cost Per Protocol

A typical 6-week BPC-157 protocol at 500 mcg/day requires approximately 3 vials (5 mg each). A typical 8-week TB-500 protocol requires approximately 4–5 vials. At similar vial prices ($35–45), total protocol costs are comparable, though TB-500 protocols tend to run slightly higher due to longer duration and higher per-dose amounts.

→ Calculate the exact cost of either protocol (or both stacked) with our Cost Calculator.

Which One Should You Choose?

Choose BPC-157 if:

You have a specific, localized injury (single tendon, ligament, or muscle)
You want the most-studied option with human safety data
You're a beginner and want to start with a single peptide
You're addressing gut or GI issues (BPC-157's origin as a gastric peptide gives it a unique advantage here)
You prefer a peptide that doesn't require a loading phase
You want a compound that also has neuroprotective research

Choose TB-500 if:

You have multiple injury sites or widespread tissue damage
Chronic systemic inflammation is a primary concern
You prefer fewer injections per week (2–3 vs daily)
You're looking for systemic tissue remodeling rather than localized repair
You want the longer half-life for more stable blood concentrations

Choose both (the stack) if:

You want maximum repair potential from complementary mechanisms
You have a significant injury that you want to address aggressively
You're experienced with peptides and comfortable managing a multi-compound protocol
Budget allows for both compounds simultaneously

The BPC-157 + TB-500 Stack

This is the most widely used peptide stack in the tissue repair category, and it exists because the two peptides address healing from genuinely different angles.

BPC-157 builds new blood vessels to supply the repair site with nutrients and oxygen. TB-500 mobilizes repair cells to migrate to the damaged area and reduces the inflammatory barrier to healing. Together, you get both the infrastructure (blood supply) and the workforce (migrating repair cells) that tissue healing requires.

Stack Protocol (Intermediate)

Peptide	Phase	Dose	Frequency	Duration	Route
BPC-157	Continuous	500 mcg	2x daily	8 weeks	SubQ near injury
TB-500	Loading	2.5 mg	2x/week	Weeks 1–4	SubQ (any site)
TB-500	Maintenance	1.5 mg	1x/week	Weeks 5–8	SubQ (any site)

Key timing notes:

BPC-157 and TB-500 can be injected at different times of day
BPC-157 should be injected as close to the injury site as possible
TB-500 can be injected at any convenient SubQ site (abdomen, thigh)
They should not be mixed in the same syringe

→ Build a customized repair protocol in the Protocol Builder — select "Tissue Repair" and your experience level.

→ Verify this combination in the Interaction Checker — rated "Strong Synergy."

Dosing Protocols Compared

BPC-157

Protocol	Dose	Frequency	Duration	Route
Standard Repair	250 mcg	1–2x daily	4–6 weeks	SubQ near injury
Aggressive Repair	500 mcg	2x daily	4–8 weeks	SubQ near injury
GI / Gut Healing	500 mcg	2x daily	4–8 weeks	SubQ (abdominal) or Oral
Systemic / General	250 mcg	1x daily	4 weeks on / 2 off	SubQ (rotating)

TB-500

Protocol	Dose	Frequency	Duration	Route
Loading Phase	2–5 mg	2x/week	4 weeks	SubQ (any site)
Maintenance	1–2 mg	1x/week	4–8 weeks	SubQ (any site)
Aggressive Loading	5 mg	2x/week	4 weeks	SubQ (any site)

→ Calculate your exact dosage and syringe units for either peptide with our Reconstitution Calculator.

Side Effects Compared

BPC-157 Side Effects

Most reported side effects are mild and transient: nausea (typically at higher doses), dizziness (uncommon), injection site redness, headache (rare), and fatigue during the first few days. The 2025 human pilot study reported no serious adverse events at IV doses up to 20 mg.

TB-500 Side Effects

Similarly mild in reported cases: headache (the most common report), injection site irritation, fatigue, and lightheadedness. Some users report a brief "flushing" sensation after injection. TB-500 has no published human clinical trial data for formal safety assessment.

Shared Contraindications

Both peptides promote tissue growth processes that could theoretically support tumor growth. Most practitioners recommend avoiding both BPC-157 and TB-500 if you have active cancer or a history of cancer within the past 5 years. Both should be avoided during pregnancy and breastfeeding due to lack of safety data.

Legal Status

As of April 2026, both BPC-157 and TB-500 were placed on the FDA's Category 2 restricted list in 2023–2024, which limits their availability through 503A compounding pharmacies. However, the Pharmacy Compounding Advisory Committee (PCAC) is actively reviewing several restricted peptides for potential reinstatement, and the regulatory direction suggests these compounds may return to compounding availability through Q2–Q3 2026.

Both remain available as research chemicals from various vendors, though these products are labeled "not for human consumption" and are not regulated for therapeutic use.

→ Track the latest regulatory developments on our Regulatory Dashboard.

Frequently Asked Questions

Can I take BPC-157 and TB-500 at the same time? Yes — this is the most common peptide stack in the repair category. They work through complementary mechanisms and are rated "Strong Synergy" in our Interaction Checker. Inject them separately (not in the same syringe) and at different sites if needed.

Which works faster — BPC-157 or TB-500? BPC-157 typically shows noticeable effects sooner (1–2 weeks) due to its localized angiogenesis mechanism. TB-500's systemic effects often take 3–4 weeks to become apparent, partly because the loading phase must build tissue saturation before full effects emerge.

Can I take BPC-157 or TB-500 orally? BPC-157 has some research supporting oral administration, particularly for GI-related applications. Oral bioavailability is lower than injectable, but some users report benefits. TB-500 is not typically taken orally — its larger molecular weight (4,963 Da) makes oral absorption unlikely.

Do I need to cycle BPC-157 or TB-500? BPC-157 is typically run for a set duration (4–8 weeks) and then discontinued. It does not require formal cycling in the way GH secretagogues do. TB-500 naturally incorporates cycling through its loading/maintenance structure, followed by a break.

Can I use BPC-157 or TB-500 with GH secretagogues? Yes. BPC-157's GH receptor upregulation may actually enhance the effects of GH secretagogues like CJC-1295/Ipamorelin. TB-500 is compatible with GH secretagogues as well. Check your specific combination in our Interaction Checker.

Sources

Seiwerth, S. et al. (2018). BPC 157 and Standard Angiogenic Growth Factors. Gastric Pentadecapeptide BPC 157 in Wound Healing. Current Pharmaceutical Design, 24(18), 1972–1989. PMID: 29756563
Chang, H. et al. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules, 19(11), 19066–19077. PMID: 25401642
Gwyer, D., Wragg, N. M., & Wilson, S. L. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(2), 153–159. PMID: 31203428
Kleinman, H. K., & Sosne, G. (2016). Thymosin β4 and the eye: I. Corneal wound healing. Annals of the New York Academy of Sciences, 1374(1), 188–195. PMID: 27411715
Sosne, G., Qiu, P., & Goldstein, A. L. (2012). Thymosin beta 4 and the eye. Annals of the New York Academy of Sciences, 1269(1), 92–98. PMID: 23045976
Crockatt, M. (2025). IV BPC-157 Safety in Humans at Doses Up to 20mg. Phase I Pilot Study. PMID: 39284103

Medical Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. The peptides discussed are not FDA-approved for therapeutic use. Always consult a licensed healthcare professional before beginning any peptide protocol.

Disclaimer

This article is for educational purposes only and does not constitute medical advice. Consult a licensed medical professional before considering any peptide therapy.

← All articles